Back to Search
Start Over
Alirocumab's Price Reduction.
- Source :
-
Circulation . 10/9/2018, Vol. 138 Issue 15, p1502-1504. 3p. - Publication Year :
- 2018
-
Abstract
- The article focuses on issues related to cost-effective pricing of Alirocumab and another PCSK9 inhibitor, evolocumab, which were priced at more than 14,000 dollars annually following the U.S. Food and Drug Administration's approval in 2015. It highlights the failure of these high prices to meet conventional cost-effectiveness thresholds with enormous budgetary implications raised by the widespread PCSK9 inhibitor adoption.
- Subjects :
- *DRUG prices
*COST effectiveness
*DRUG development
*DRUG approval
*ANTILIPEMIC agents
*COMPARATIVE studies
*HEALTH services accessibility
*RESEARCH methodology
*MEDICAL care costs
*MEDICAL cooperation
*MONOCLONAL antibodies
*RESEARCH
*EVALUATION research
INDUSTRIES & economics
BUSINESS & economics
Subjects
Details
- Language :
- English
- ISSN :
- 00097322
- Volume :
- 138
- Issue :
- 15
- Database :
- Academic Search Index
- Journal :
- Circulation
- Publication Type :
- Academic Journal
- Accession number :
- 132198882
- Full Text :
- https://doi.org/10.1161/CIRCULATIONAHA.118.036069